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Abstract
ZEB1 and ZEB2 play pivotal roles in solid cancer metastasis by allowing cancer cells to invade and disseminate through the
transcriptional regulation of epithelial-to-mesenchymal transition. ZEB expression is also associated with the acquisition of cancer
stem cell properties and therapy resistance. Consequently, expression levels of ZEB1/2 and of their direct target genes are widely
seen as reliable prognostic markers for solid tumor aggressiveness and cancer patient outcome.
Recent loss-of-function mouse models demonstrated that both ZEBs are also essential hematopoietic transcription factors
governing blood lineage commitment and ﬁdelity. Interestingly, both gain- and loss-of-function mutations have been reported in
multiple hematological malignancies. Combined with emerging functional studies, these data suggest that ZEB1 and ZEB2 can act as
tumor suppressors and/or oncogenes in blood borne malignancies, depending on the cellular context. Here, we review these novel
insights and discuss how balanced expression of ZEB proteins may be essential to safeguard the functionality of the immune system
and prevent leukemia.
ZEB1 and ZEB2: 2 structurally related E-box-
binding transcription factors
The ZEB (Zinc ﬁnger E-box-binding homeobox) protein family
of transcription factors was discovered in Drosophila mela-
nogaster and consists of 2 structurally conserved multidomain
proteins, ZEB1 (originally called ZFHX1A, TCF8, or dEF1)
and ZEB2 (originally called ZFHX1B or SIP1).1,2 Both ZEBs
contain an amino-terminal (NZF) and carboxy-terminal zinc
ﬁnger cluster (CZF), which enables them to bind regulatory
DNA sequences in their target promoters. Each zinc ﬁnger
cluster binds an independent 50-CANNTG-30 motif, which
overlaps with the core of an E2-box sequence,3–5 a binding site
for transcription factors of the basic helix-loop-helix (bHLH)
family. ZEBs can repress target gene transcription through the
recruitment of the CtBP corepressor complex via their CtBP
interaction domain (CID).6 Additional conserved domains
were documented by which ZEBs can recruit other transcrip-
tional complexes to their target promoters. For instance,
the amino-terminus of both ZEBs can bind the Nucleosome
Remodeling and Deacetylase complex (NuRD, also known
as the Mi-2 complex).7,8 Also, a SMAD Binding Domain (SBD)
is located between theNZF and the central homeobox domain.4
Although this SBD is highly conserved and both ZEBs can
directly interact with SMADs, they may have an opposite
downstream effect9: ZEB1 synergizes with SMAD proteins
to activate SMAD-mediated transcription, while ZEB2 seems
to inhibit SMAD-mediated transcription. It is believed that
this opposite effect is regulated by the differential recruitment
of ZEB1/2-speciﬁc coactivators/repressors, which may be
tissue-speciﬁcally expressed. Initially, the N-terminal region
of ZEB1, but not ZEB2, was documented to interact with
p300 and P/CAF. This differential recruitment of P/CAF may
switch ZEB1 from a repressor to an activator through the
displacement of CtBP1 from the CID.9,10 Later, others
demonstrated that, depending on the experimental context,
ZEB2 and ZEB1 are equally potent to bind p300 and P/CAF.11
This suggests that other mechanisms/cofactors are contributing
to the differential ZEB1/2-speciﬁc effects on SMAD-mediated
transcription.
Based on the extensive and continuously growing list of
interaction partners and putative downstream targets, one can
expect that ZEBs have very pleiotropic functions, which largely
depend on the cellular context. Indeed, the chromatin status and
the presence/absence of tissue-speciﬁc interaction partners
strongly inﬂuence their role as a transcriptional repressor/
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activator. This can, to some extent, explain why in some cell types
ZEBs play complementary or synergistic roles while in others
seemingly opposite roles.
ZEBs are master regulators of (cancer) cell
plasticity
ZEBs during EMT
ZEB proteins are primarily known as inducers of epithelial-
mesenchymal transition (EMT), a reversible multistep process
during which polarized epithelial cells undergo a morphological
switch to become motile mesenchymal cells that have lost their
polarity.12 ZEBs orchestrate EMT by the direct repression of
epithelial genes involved in cellular adhesion and cytoskeleton
(re)organization,3,13,14 and subsequent direct or indirect upre-
gulation of mesenchymal genes.15,16 This epithelial-to-mesen-
chymal cell plasticity is essential at various stages of embryonic
development, but also often seen aberrantly activated in cancer
cells.12 Induced expression of ZEB1 or ZEB2 in xenotransplanted
epithelial cancer cells endows them to invade and disseminate
from the primary tumor site. These circulating tumor cells will
then need to undergo a reversed process called mesenchymal-
epithelial transition or MET to colonize a distant tissue and grow
out as a metastasis.
In addition, EMT-inducing transcription factors (EMT-TF),
like ZEB1 and ZEB2, are more than “only” regulators of cancer
cell invasion and they dictate multiple other steps during cancer
initiation and progression.17 Increased ZEB expression has been
correlated with the acquisition and/or function of cancer stem cell
(CSC) properties.18–20 CSCs or tumor-initiating cells have the
potential to self-renew and form secondary tumors when
transplanted into immune deﬁcient or syngeneic mice. The
molecular mechanisms controlled by EMT-TF that induce these
CSC properties remain elusive until today.17,19 In addition, a
large body of literature suggests that CSC subpopulations are
responsible for emerging residual subpopulations following
radiotherapy, chemotherapy, or other targeted therapies. Also
EMT-TF-driven cancer cell plasticity facilitates drug adaptation
and protects the cancer cells against genotoxic insults and
therapy-induced stress via enhanced cell survival, induced DNA
damage repair,21,22 antiproliferative mechanisms,23 and in-
creased expression of genes encoding drug-metabolizing enzymes
and drug-transporters.24 As such, ZEBs can act as important
regulators of therapy resistance.
Next to ZEB proteins, also SNAI and TWIST transcription
factors have been demonstrated to catalyze similar EMT
phenotypes in the context of solid tumors.12,17 Consistent results
in cancer cell lines suggest cooperativity between the different
EMT inducers with complex regulatory feedback mechanisms
involving Notch signaling and the miR-200 family.25
To conclude, the pivotal roles of the EMT modulators in solid
tumor progression have been extensively documented. It is
therefore no surprise that ZEB expression levels and the
expression of their targets are used in the clinic as reliable
prognostic markers for solid tumor aggressiveness and poor
patient outcome.
Emerging roles of ZEB proteins in hematopoiesis
Gain- and loss-of-function mouse models revealed that ZEB
proteins also play pivotal roles in cellular plasticity of other cell
lineages, including the hematopoietic lineage.
Next to the fullZeb1 knockout, which is perinatal lethal due to
skeletal defects,26 2 other Zeb1mutant mouse models expressing
truncated C-terminal ZEB1 deletions lacking the CZF domain
have been generated.26–28 The ﬁrst one, Zeb1DC-ﬁn mice have a
profound thymic atrophy with spontaneous development of
CD4+ T-cell lymphoma at older age.29 Their hypocellular thymi
show an increased proportion of CD4/CD8 double negative cells
and a drastic reduction in double positive cells, suggestive of an
early partial block in T-cell development.27 The few Zeb1DC-ﬁn
thymocytes that can circumvent this early block and differentiate
into mature T-cells are skewed toward the CD4+ T-cell lineage. In
line with this, previous work has shown that ZEB1 can directly
regulate CD4 expression by competing with transcriptional
activators E12 and HEB for the binding to an E-box-containing
enhancer of the CD4 promoter.30 The Zeb1cellophane mice, the
secondZeb1mutantmodel with a C-terminal truncation, are also
characterized by hypocellular thymi that display an early T-cell
differentiation block. Detailed analysis of other lineages
suggested B-cell and NK-cell maturation defects in the spleen
of these Zeb1 mutant mice.28 Until now, it is unclear whether
these defects are cell autonomous or due to aberrant paracrine
signaling. Similarly, it remains to be established whether these
truncated ZEB1 versions are true loss-of-function mutations and/
or can act in a dominant negative manner. A recently generated
conditional Zeb1ﬂ/ﬂ knockout mouse line31 will allow further
investigation of the role of Zeb1 in speciﬁc hematopoietic
lineages.
The role of Zeb2 in hematopoiesis has been studied with
conditional loss- and gain-of-function mouse models.32,33
Inactivation of Zeb2 in the hematopoietic lineage resulted in
vast multilineage differentiation defects, associated with an
accumulation of stem and progenitor cells and a signiﬁcant drop
in fully matured functional blood cells.34,35 Differentiation
defects appeared at early and later stages of hematopoiesis
affecting most lineages, except the granulocytes. These studies
were extended by using more lineage-restricted Cre-lines
allowing to demonstrate essential roles for ZEB2 for NK-cell
maturation,36 terminal differentiation of CD8+ cytotoxic T-
cells,37,38 and dendritic cell (DC) development.39 In addition,
strong evidence suggests that ZEB2 is also important for
Langerhans cell40 and mast cell maturation/activation,41 al-
though the latter is purely based on in vitro work and the
relevance of these observations will have to be conﬁrmed in vivo.
Altogether, these studies suggest that ZEB2 is a transcription
factor that controls lineage commitment and ﬁdelity at various
stages of hematopoiesis. In addition, ZEB2 is crucial for proper
immune functioning and loss of Zeb2 can lead to defective
response to pathogens.
Based on the observed complementary expression patterns of
Zeb1 and Zeb2 mRNAs during embryonic development and
aggravated phenotypes in compound Zeb1/Zeb2 loss-of-
function mice, it was suggested that ZEB transcription factors
may have partly overlapping, compensatory functions.42
Remarkably, we observed that Zeb1 and Zeb2 mRNA
expression is also mostly mutually exclusive during hemato-
poietic differentiation, except in the hematopoietic stem and
multipotent progenitor cell (HSPC) compartment where Zeb1
and Zeb2 are co-expressed at moderate levels (Fig. 1). Once
lineage commitment is initiated, counter-oscillating levels of
both mRNAs are observed with fast Zeb1/2 switching at
distinct cell fate decision points. In addition, most of the
hematopoietic differentiation defects seen in theZeb1/2 loss- or
gain-of-function mouse models occur exactly at these decision
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checkpoints (Fig. 2, examples are shown for the T-cell lineage
[upper panel] and dendritic cell lineage [lower panel]). Based on
these observations, one could hypothesize that oscillations of
ZEB levels may control hematopoietic differentiation. At this
point, the molecular mechanisms that control such a Zeb
mRNA switching remain largely unexplored. However, nega-
tive feedback mechanisms via the miRNA-200 family might
partially explain these Zeb1/2 oscillations.25,43 Indeed,
miRNA-200 family members are able to inhibit expression of
ZEB1/2 at the post-transcriptional level by binding to highly
conserved target sites in their 30-untranslated region. In
addition, ZEBs are also able to transcriptionally repress the
miRNA-200 family, suggesting a negative feedback loop that
can fuel this ZEB1/2 switching. Interestingly, also in non-
hematopoietic cell lineages, including themelanocytes, a similar
oscillation betweenZeb1/2mRNAs has been described.44,45 Of
note, this concept has also been suggested for other protein
families, including the GATA2/GATA1 switch as an important
driver of molecular development.46 However, this ZEB switch-
ing hypothesis does not exclude that ZEB1 andZEB2 could also
have family member-speciﬁc functions, which may be depen-
dent on the cellular context.10
Figure 1. Zeb1 and Zeb2 aremostly mutually exclusive expressed during hematopoietic differentiation. The ﬁgure is based on expression data available
via http://servers.binf.ku.dk/bloodspot/. CLP= common lymphoid progenitor, GMP = granulocyte monocyte progenitor, HSC = hematopoietic stem cell, IgM+ SP
= IgM positive side population, MEP =megakaryocytic erythroid progenitor, MPP =multipotent progenitor, PreB = Pre-B cell, ProB = Pro-B cell, pro-NK = natural
killer cell progenitor, T-CD4 = T-cell CD4+ single positive, T-CD8 = T-cell CD8+ single positive, T-DN = T-cell CD4CD8 double negatives, T-DP = T-cell
CD4+CD8+ double positives.
(2018) 2:3 www.hemaspherejournal.com
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Genetic alterations of ZEBs in leukemia and
lymphoma
Based on the importance of ZEB expression during normal
hematopoiesis, and their pleiotropic roles in progression of solid
cancers, it is expected that ZEB1 andZEB2 could also play pivotal
roles in hematologicmalignancies. Indeed, both genetic and in vivo
functional studies indicate that ZEBs can act, depending on the
lineage, as oncogenic drivers and/or tumor suppressors (Fig. 3).
ZEBs in T-cell malignancies
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
hematological cancer of thymic T-cell progenitors that gradually
accumulate epigenetic and genetic changes, leading to a block in
differentiation, increased survival and proliferative expansion of
a malignant clone.47,48 Over the last decade, the prognosis of T-
ALL has gradually improved with the introduction of intensiﬁed
chemotherapy. However, the outcome of T-ALL patients with
primary resistant or relapsed disease remains poor.49
A rare (0.2%; 2/1084 patients), but recurrent, t(2;14)(q22;
q32) translocation involving the ZEB2 and BCL11B loci has
been identiﬁed in early T-cell progenitor ALL (ETP-ALL),18 a
heterogeneous subgroup of T-ALL with a unique gene expression
proﬁle similar to that of the most immature ETPs.50,51 It was
hypothesized that this translocation retains ZEB2 expression
during T-cell commitment leading to a differentiation block
and leukemic transformation.18 Hematopoietic-speciﬁc Zeb2
Figure 2. Examples of ZEB expression switching as molecular drivers of important cell fate decisions during hematopoietic differentiation. (A)
Counter oscillating expression levels of Zeb1 and Zeb2 during T-cell differentiation with indications of known differentiation defects in Zeb1 and Zeb2 loss-of-
function mouse models. (B) Oscillating Zeb2 expression levels during dendritic cell (DC) differentiation with indications of known differentiation defects in Zeb2 loss-
of-function mouse models. CD4 = T-cell CD4+ single positive, CD8 = T-cell CD8+ single positive, cDC1 = conventional DC subtype 1, cDC2 = conventional DC
subtype 2, CDP = common dendritic cell progenitor, CLP = common lymphoid progenitor, CMP = common myeloid progenitor, DN = T-cell CD4CD8 double
negatives, DP = T-cell CD4+CD8+ double positives, GMP = granulocyte monocyte progenitor, HSC = hematopoietic stem cell, MDP macrophage/DC progenitor,
MPP = multipotent progenitor, pDC = plasmacytoid DC.
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overexpression in the mouse was sufﬁcient to spontaneously
develop T-ALL with an immature Lyl1+ expression proﬁle, with
profound similarities to the human disease.18 Overexpression of
Zeb2 resulted in increased expression of the interleukin-7
receptor (IL7R) and aberrant activation of the IL7R-JAK/STAT
signaling pathway. In addition, ZEB2 overexpression was
associated with the acquisition of enhanced leukemia stem cell
properties. Activating IL7R mutations are recurrently found in
ETP-ALL patients.50 In addition, a similar immature ETP-ALL
leukemia initiation with increased self-renewal was observed
after overexpression of a gain-of-function mutant variant of IL7R
in p19Arf/ mouse hematopoietic progenitors.52
In contrast to ZEB2, ZEB1 seems to act as a tumor suppressor
in T-cell derived hematological neoplasms. ZEB1 has been
identiﬁed as an essential downstream mediator of the LMO2
oncogene in T-ALL.53 In line with this, Zeb1 mutant loss-of-
function mice showed drastic defects in early T-cell development
and spontaneously develop T-cell lymphoma/leukemia with a
median onset of 6 months,27,54 similar to what has been observed
in LMO255,56 and ZEB2 overexpressing mice.18 Combined, these
data suggest opposing roles for ZEB1 and ZEB2 in T-ALL
initiation/progression.
Furthermore, expression analysis of genes mapped within a
common (34.6% of patients) breakpoint cluster in the 10p11.2
region of adult T-cell leukemia/lymphoma patients (ATLL),
suggested that ZEB1 may act also as a tumor suppressor in these
patients.29 ATLL is a peripheral T-cell malignancy with a mature
CD4+ immunophenotype.57 Most ATLL cell lines and primary
cells display low mRNA expression levels of ZEB1, as a
consequence of either chromosomal translocations with hetero-
zygous deletion, intragenic mutations, or epigenetic dysregula-
tion.29 Mechanistically, low ZEB1 levels may result in resistance
to TGFb1-mediated growth arrest.58 Binding of the TGFb1
ligand to its receptor activates its kinase activity, leading to
phosphorylation of receptor-associated SMAD proteins. These
phospho-SMADs accumulate in the nucleus as dimers, and in
conjunction with other transcription factors like ZEB1 and
ZEB2, they bind regulatory elements within their target gene
promoters. As an example, TGFb1 stimulation induces cell
cycle arrest in various tumor cell types59 via the direct
upregulation of the cyclin-dependent kinase inhibitor p21. ATLL
cells with low ZEB1 levels appear to be resistant to these
antiproliferative effects of TGFb1. Overexpression of ZEB1
restored the TGFb1-mediated growth suppression in these cells,
associated with increased p21 expression. Mechanistically, ZEB1
expression, and its direct binding to the phospho-SMAD3
complex, was demonstrated to be essential for the recruitment of
this complex to the SMAD-Response Element within the p21
promoter.58
Aberrant ZEB1 expression has also been linked to 2 other
lymphoproliferative T-cell disorders: mycosis fungoides and
Sézary syndrome. Mycosis fungoides is a cutaneous T-cell
lymphoma (CTCL) developing from clonally expanded skin-
homing CD4+ T-cells. Sézary syndrome can arise de novo, but
mostly occurs in patients with mycosis fungoides and can be
considered as the leukemic variant of this disease.60,61 Several
genetic alterations targeting ZEB1 have been reported in both
forms of CTCL (up to 65%), including translocations, mutations,
and both heterozygous and homozygous deletions.62–66 Loss-of-
ZEB1 expression or function has been associated with the
pathogenic role of IL15 signaling in CTCL. Either loss-of-ZEB1
expression, mutation or hypermethylation of the ZEB1 binding
sites in the IL15 promoter resulted in a vast upregulation and
activation of oncogenic signals.67 Altogether, these loss-of-
function alterations of ZEB1 suggest that the transcription factor
acts as a key tumor suppressor in peripheral T-cell lymphoma.
Figure 3. ZEBs as oncogene or tumor suppressors of leukemia. Schematic representation of known or suggestive oncogenic and/or tumor suppressive
roles for ZEB1 and ZEB2 in various leukemia subtypes.
(2018) 2:3 www.hemaspherejournal.com
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ZEBs in B-cell malignancies
Altered ZEB1 expression and mutations have been associated
with 2 types of B-cell malignancies, namely mantle cell lymphoma
(MCL) and diffuse large B-cell lymphoma (DLBCL). MCL is an
infrequent subtype of non-Hodgkin B-cell lymphoma (B-cell
NHL) with a poor response to chemotherapy.68,69 The molecular
hallmark of this disease is overexpression of cyclin D1 due to the
chromosomal t(11;14)(q13;q32) translocation. Half of MCLs
display constitutive active Wnt signaling with nuclear localiza-
tion of beta-catenin and concomitant high expression of ZEB1.
Downregulation of ZEB1 expression in MCL cell lines reduced
their tumor growth capacity in mouse xenograft models. In
addition, the cell lines with reduced ZEB1 expression were more
sensitive to chemotherapeutics, associated with a differential
expression of drug inﬂux/efﬂux transporters, and genes involved
in cell survival/apoptosis.70 Therefore, this study suggested that
ZEB1 could serve as a potential predictive biomarker and
putative therapeutic target in MCL.
DLBCL is the most frequent form of adult NHL.61 ZEB1 can
be considered as an oncogene in DLBCL for several reasons. First,
strong nuclear immunohistochemical staining for ZEB1 was
associated with an adverse 3-year overall survival of DLBCL
patients compared to those with no or weak nuclear ZEB1
staining.71 Next to this, higher levels of the miR-200 family, a
known negative regulator of ZEB1 mRNA expression levels,
results in a less aggressive behavior of this disease.72Helicobacter
pylori positive gastric DLBCLs, which typically show lower
ZEB1 expression, have less lymph node metastasis, better
response to chemotherapy, and are less aggressive. This last
subgroup is also characterized by higher expression levels of
BCL6, a known predictor of better prognosis in DLBCL73 and a
direct target of ZEB1.74 Combined, these expression data suggest
that ZEB1 may act as an oncogene in these 2 B-cell NHL forms.
Interestingly, loss and not gain of 2q22.3, the genomic region
spanning the ZEB2 locus, has been recurrently (18.75%)
observed in B-cell lymphoma patients.75 In addition, rare but
recurrent (7.2%) somatic ZEB2 point mutations were found in B-
cell precursor acute lymphoblastic leukemia (B-ALL). B-ALL is
the most common childhoodmalignancy that initiates in the bone
marrow (BM)with oncogenic transformation of B-cell progenitor
cells.76 In all 5 reported B-ALL patients with mutantZEB2 locus,
a single AA mutation speciﬁcally affected the carboxy-terminal
Cys2His2 Zinc ﬁngers,8 which have proven to be essential for the
DNA binding and E-box recognition capacity of ZEB2.3
Notably, all of these patients had a very similar expression
proﬁle, associated with deregulated expression of ERG8,77
(https://pecan.stjude.org/proteinpaint/ZEB2). The fact that these
mutations are uncommon in other B-ALL subtypes, suggests that
loss of the ZEB2 DNA binding capacity may be involved in the
progression of this disease, which comprises up to 7% of all B-
ALLs. The same laboratory also reported a ZEB2-PDGFRB
translocation in 1 B-ALL patient. In this translocation event, the
carboxy-terminal zinc ﬁnger domain of ZEB2 is missing and in
frame fused to the catalytic domain of the Platelet-derived
Growth Factor Receptor-B77,78 (https://pecan.stjude.org/protein
paint/ZEB2). However, no additional data are available whether
this chimeric protein is expressed, functional and whether it
contributed to the disease progression. The notion that ZEB2, or
a mutant version, may play an important role in the initiation
and/or progression of B-ALL is further supported by the observed
high occurrence of viral insertions at the Zeb2 locus in 2
independent retroviral mutagenesis screens using mouse models
that are predisposed to develop spontaneously B-ALL, the
CALM-AF10 transgenic and heterozygote Pax5/+ mice.79,80
However, no information is available whether these viral
integrations result in loss- or gain-of-Zeb2 functions.
Combining the mutation data of the human patients and the
mutagenesis screenings in the B-ALL mouse models, we
hypothesize that ZEB2 acts as a tumor suppressor in B-cell
malignancies, in contrast to ZEB1, which seems to act as an
oncogene. More research will be necessary with conditional
Zeb1/2 gain/loss-of-function mouse models using a B-cell
restricted Cre line to further test this hypothesis.
ZEBs in myeloid malignancies
Acute myeloid leukemia (AML) is a clinically and genetically
heterogeneous malignancy, characterized by uncontrolled accu-
mulation of immature myeloid cells mostly in the blood and the
BM of the patient. This accumulation of blast cells in the BM
interferes with normal hematopoiesis and leads to a general
deﬁciency of hematopoietic cells. AML is understood as the
product of a rather limited number of genetic alterations
including balanced chromosomal translocations. The MLL1
histone 3 lysine 4 (H3K4) methyltransferase (aka KMT2A,
ALL1, TRX) has been found involved in over 100 leukemia-
associated rearrangements of which the MLL-AF4, MLL-ENL,
and MLL-AF9 are among the most prevalent.81 Several MLL
fusions have been shown to be potent oncogenes in vitro and in
vivo in murine as well as in human cells.82,83 Recently, a
conditional mouse model was used to address the role of the
cellular origin of MLL-AF9+ AML in the biology and clinical
outcome of the disease. Activation of MLL-AF9 in long-term
hematopoietic stem cells (LT-HSC) induces a particularly
invasive and chemoresistant disease.84 Strikingly, about 10%
to 20% of human AMLs express a very similar gene signatures
like LT-HSC-derived MLL-AF9 AMLs in mice, which is
characterized by expression of high Zeb1 mRNA levels.
Chromatin immunoprecipitation (ChIP) experiments suggested
that Zeb1 is a direct target of the MLL-AF9 fusion. Interestingly,
knockdown of Zeb1 expression compromised the invasive
behavior of MLL-AF9 AML cells in vitro and in vivo. Notably,
LT-HSC-derivedMLL-AF9 AML cells were also characterized by
increased expression of many genes regulating migration and
invasion, and thus showing at least at the transcriptional level
some similarities to that of solid cancer cells undergoing EMT.
In addition to ZEB1, increasing evidence also suggests an
important role for ZEB2 in AML development. An AML patient
was found with tumor cells carrying a similar t(2;14)(q22;q32)
translocation, as earlier identiﬁed in immature T-ALL, involving
the ZEB2 and BCL11B loci.85 In the resulting ZEB2-BCL11B
fusion transcript, the ﬁrst 19AA of BCL11B are replaced by the
ﬁrst 24AA of ZEB2. As all functional domains of BCL11B are
retained in this fusion product and the inverse BCL11B-ZEB2
transcript could not be detected, the authors concluded that the
principal result of this translocation is aberrant expression of
BCL11B controlled by the ZEB2 promoter/enhancer. Interest-
ingly, other genetic events driving BCL11B overexpression have
been reported in AML, further reinforcing the putative oncogenic
role of BCL11B in the myeloid lineage.86,87 These observations
are in sharp contrast with the proposed role of BCL11B in T-ALL
as a tumor suppressor. These data therefore suggest that a similar
genetic aberration, t(2;14)(q22;q32), can drive leukemic trans-
formation both in the myeloid as well as the lymphoid lineage. In
the case of AML, BCL11B overexpression most probably drives
Soen et al. ZEBs in Leukemia
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malignant transformation whereas retained ZEB2 expression
during T-cell commitment is most probably the oncogenic driver
in the case of immature T-ALL.18 Although the authors mainly
focused on the role of BCL11B, it should be noted that ZEB2
mRNA levels in this t(2;14)(q22;q23) positive AML patient
were normal, and most likely compensated by the unaffected
allele via downregulation of the miR-200 family.88 More recent
experiments convincingly showed that ZEB2 expression is
essential for maintenance of leukemic growth of AML.88,89
Using an in vitro genome-wide shRNA screening method,
followed by an in vivo secondary screen using a murine AML
model driven by retroviral expression of anMLL-AF9 fusion, the
authors identiﬁed ZEB2 as an essential gene for AML
progression. Further molecular analysis demonstrated that
ZEB2 represses transcription of genes important in myeloid
differentiation. Consequently, ZEB2 depletion in AML cells will
force differentiation of the leukemic cells. Interestingly, the
notion that AML cells depend on sustained ZEB2 expression was
recently conﬁrmed by a large-scale deep RNAi screen that
unraveled cancer dependencies in an extensive series of human
tumor cell lines, including AML90 (Fig. 4).
In a recent study, recurrent focal deletions of ZEB2 were found
in pediatric AML patients (6.6%; 13/197 patients).91 Unfortu-
nately, no expression data were presented in this study to
conclude whether these single-allele mutations indeed resulted in
loss-of-ZEB2 expression and/or functionality.
Similarly, whole genome sequencing identiﬁed ZEB2 putative
loss-of-functionmutations in 16%of blastic plasmacytoid dendritic
cell neoplasm (BPDCN) patients.92 BPDCN is a very rare and
aggressive myeloid neoplasm originating from precursors of a
specialized subset of DCs,93–95 with no deﬁned standard of care.
ZEBs in pathogen-induced hematologic
malignancies
ZEB2 expression has been shown to be essential for differentia-
tion, maturation, and/or function of CD8+ cytotoxic T cells
(CTLs) andNK cells, 2 types of immune cells involved in antiviral
host defense.36,38 Interestingly, recurrent deletions of the ZEB2
locus are signiﬁcantly enriched in the hepatitis C virus (HCV)-
related NHL patients.75,96 HCV is a known risk factor to develop
B-cell lymphomas. The most convincing evidence is the
observation of B-lymphoma regression after HCV eradication
by antiviral therapy.
This was further supported by the fact that viral integrations at
the Zeb2 locus are sufﬁcient to induce leukemia in mice
haplosufﬁcient for Pax5.79,80 This Pax5/+ mouse model
spontaneously develops B-ALL only in a conventional animal
house and not under speciﬁc pathogen-free conditions suggesting
that exposure to infectious agents can act as a trigger for the
development of B-ALL.97 The expression of ZEB2 may be
essential for the functionality of the innate and adaptive immune
system to efﬁciently eradicate these pathogens, but also infected
and (partially) transformed cells from the body, before they can
develop into an overt lymphoma/leukemia. We recently demon-
strated that ZEB2 also plays a pivotal role in the immunosur-
veillance and clearance of melanoma cells after transplantation in
syngeneic mice,36 suggesting it could serve as a more common
mechanism also outside of hematologic malignancies.
Also, altered expression of ZEB1 has been seen in a few
pathogen-induced leukemia/lymphoma subtypes, like H pylori
positive gastric DLBCLs71 and ATLL, which is associated with
HTLV-1 infection.29 Infections typically occur around birth and
HTLV-1 carriers have a cumulative risk of 2.5% to develop
ATLLwith an average latency of 55 years, suggesting the need for
extra tumorigenic events. However, no studies have been
reported yet that speciﬁcally investigated the role of ZEB1 in
the defense system of the body against infectious agents.
It has been estimated that over 90% of the world’s population
is carrying the Epstein-Barr herpes virus (EBV) usually acquired
by an infection, often asymptomatic, during childhood. EBV has
been linked to many types of malignancies including several
epithelial cancers and some B-cell malignancies, such as Burkitt
and Hodgkin lymphoma. EBV causes either a latent infection
Figure 4. ZEB2 is cancer dependency factor in various hematopoietic and leukemia/lymphoma cell lines. Scatter plot Dependency versus Expression.
This ﬁgure is based on data available via https://depmap.org/rnai/genedeps?gene=ZEB2,90 ﬁltered on “hematopoietic and lymphoid.” Dependency for ZEB2 was
determined in a genome-scale loss-of-function study in diverse cancer cell lines. DEMETER is an analytical that segregates on- from off-target effects of RNAi. This
ﬁgure clearly depicts that large proportion of the analyzed leukemia cell lines do express ZEB2 and are dependent on it, with negative ZEB2 DEMETER z-score.
RPKM = reads per kilobase per million mapped reads.
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which is maintained stably in the host or a lytic phase with active
production of viral particles and killing of the host cell.98 This
latent-lytic switch can be initiated by expression of the viral
immediate-early BZLF1 gene, a transactivator of viral genes for
lytic replication. Interestingly, ZEB proteins are directly involved
in the transcriptional regulation of BZLF1.99–101 For example, in
B-cell lymphocytes, ZEB1 binds 2 consensus ZEB binding sites in
the proximal promoter of the BZLF1 gene to actively repress its
transcription. Therefore, inhibition of ZEB1 could be a potential
mechanism to break through latency, activate the lytic phase of
infection, leading to dead of the virally infected malignant cells.
Therefore, ZEB expression may have a direct effect on the viral
infectious cycle independent of the immune system and, as such,
affect the initiation of EBV-related B-cell lymphomas.
ZEB downstream signaling in epithelial and
hematopoietic cells
ZEB downstream signaling events have mostly been studied in
epithelial cells. Differential gene expression analysis upon drug-
inducible ZEB1/2 expression resulted in an extensive list of
putative ZEB1/2 target genes in the context of EMT.13,16 Most of
these genes are involved in cellular adhesion, cytoskeletal
reorganization, cell polarity, and extracellular matrix composi-
tion. Subsequent promoter reporter studies in combination with
ChIP identiﬁed a common ZEB recognition site consisting of a
double E/Z-box in promoters of epithelial marker genes repressed
by ZEB1/2.3,14 How ZEBs can activate mesenchymal promoters
is less understood. Recent work suggested that ZEB1might act as
a direct activator in a complex with others transcription factors,
like YAP1102 (Fig. 5A). Based on in silico predictions, in
combination with in vitro studies using epithelial cancer cell lines,
the spectrum of downstream targets of ZEB1/2, at least in the
context of EMT, is relatively well established.
In contrast to solid tumor cells, the ZEB transcriptional targets
in hematopoietic cells only start to emerge. Gene expression
proﬁling after conditional loss of ZEB2 identiﬁed putative
effector genes involved in cellular adhesion/homing and
chemotaxis (Cxcr3, Cxcr4, Cxcr5, S1PR5, Cxcr3r1, Itgb2,
Ccr7, Epcam, a4-integrin)35–39 as well as lineage-speciﬁc
cytokines (IL2, IL7R, IL15, IL6, G-CSF).6,18,34,38,48,103 Interest-
ingly, a large proportion of these genes are known targets of
E2A.38 E-proteins are widely expressed bHLH transcription
factors that cooperate with tissue/lineage-speciﬁc bHLH proteins
by forming heterodimers that recognize a single E-box in their
target promoter.104 Id (Inhibitors of DNA binding) proteins
counteract E-protein function. They lack a basic DNA-binding
domain and tether E-proteins and other bHLH proteins away
from E-boxes by forming heterodimers thereby preventing
transcriptional E2A activation. Both E-proteins and Id proteins
have been shown to play essential roles in hematopoiesis,105
lymphocyte development, and lymphoid disease,106 and have
been identiﬁed as master regulators of CSC and cancer
aggressiveness.107 Therefore, competition between ZEBs and
tissue-speciﬁc E-protein heterodimers, that bind similar or
overlapping DNA recognition sites, could partially explain the
ZEB lineage-speciﬁc downstream effects30,108–110 (Fig. 5B).
Interesting to note in this context is the similarity in function
between ZEBs and LMOs. Indeed, while ZEB proteins directly
bind bipartite E-boxes via their amino and carboxyterminal zinc
ﬁnger domains, LMOs are part of a multiprotein transcription
complex that can also bridge 2 distant E-protein heterodimers.
Interestingly, these similarities might explain the observed
phenotypic similarities between ZEB2 overexpression and
LMO2 overexpression in the context of T-ALL, spontaneous
immature T-ALL formation associated with gain of self-renewal
and stem cell properties18,55,56,111,112 (Fig. 6).
We noted that multiple ZEB binding sites in promoters of
differentially expressed genes upon ZEB2 knockout in NK cells
and CD8+ CTLs,36,38 partially overlap with T-box recognition
sites, suggesting that also ZEBs and T-box binding proteins, such
as T-bet/Eomes, could inﬂuence each other’s DNA binding
capacity and transcriptional activity. Such a cross-competition
may explain some of the overlapping or synergistic functions in
Figure 5. Various modes of ZEBs transcriptional activity. (A) ZEBs recognize via their zinc ﬁnger clusters E-box sequence, which partially overlap T-box
recognition sites. ZEBs may therefore compete or affect the function of other tissue-speciﬁc transcription factors that recognizes these similar regulatory regions,
like E-proteins, Id proteins, and the T-box recognition proteins Eomes and T-bet. (B) ZEBs directly repress/activate target promoters via the recruitment of co-
activator/repressor complexes or indirectly via altering chromatin landscape and promoter accessibility. E = E-protein.
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different hematopoietic lineages36–38 (Fig. 5B). More research will
be necessary to fully understand the synergistic and competitive
interactions between these E- and T-box binding transcription
factor families. Also competitive or synergistic functions of ZEB
proteins with other transcription factor families needs further
investigation.As example, Zeb1 indirectly regulates the expression
of a4-integrin by inhibiting the transcriptional activity of c-Myb
and Ets individually. However, synergy between c-Myb and Ets
can overcome this repression, and highlights the ﬁne balance and
complex interactions between ZEB proteins and other essential
hematopoietic transcription factors.113
The combination of the above-described oscillating ZEB1/2
expression, the cell-state speciﬁc chromatin accessibility, the
competition with multiple other transcription factors’ families
for DNA binding, and the presence or absence of coactivators and
repressors, suggests that the transcriptional regulation of ZEB
target genes is highly dynamic and cell type-speciﬁc resulting in
differentphenotypes in the loss- andgain-of-functionmousemodels
affecting various stages of normal and malignant hematopoiesis.
Interestingly, EMT transcription factors of the SNAI family are
also expressed during hematopoiesis114 and evidence is accumu-
lating that they are also involved in malignant transformation
toward leukemia.115 Further research will be necessary to
determine whether they use similar converging/complementary
pathways in the context of leukemia, as was previously observed
during carcinoma progression.12,17
Conclusion
Until recently, ZEB proteins have mainly been studied as EMT
inducing transcription factors allowing dissemination of epithe-
lial cancers from the primary tumor site, and gaining stem cell
properties and features for therapy resistance. Although EMT is
not a hallmark of hematologic malignancies, we here enlisted
extensive evidence that ZEBs do also play an important role in
initiation and progression of different subtypes of lymphomas
and leukemias.
Depending on the lineage of origin of these malignancies,
ZEB1/2 can both act as oncogenes or tumor suppressors. In
certain T-cell malignancies, ZEB1 can be considered as a tumor
suppressor and ZEB2 as an oncogene, whereas this seems to be
opposite for B-cell malignancies. Finally, in AML, both TFs can
act as oncogenes and/or dependency factors. These often
contradictory, synergistic, and/or complementary functions of
ZEBs on lymphoma/leukemia initiation, progression, or mainte-
nance may be, at least in part, explained by their very pleiotropic
functions (cellular adhesion and mobilization/homing, stem cell
properties and therapy resistance, immune regulation) at various
stages during hematopoiesis; but may also be inﬂuenced by
their complex oscillating expression proﬁle, in combination with
the presence/absence of cell-context dependent cofactors and
downstream targets.
This raises the question if it would be feasible to therapeutically
target ZEBs in the context of leukemia. Nevertheless, next to the
inherent difﬁculty of targeting transcription factors, the main
concern for therapeutic inhibition or reactivation of ZEB
proteins might reside in the possible side effects. Indeed,
ZEB1/2 have physiological functions throughout the body,
including control of the immune system, where they safeguard
development and functioning of different immune cell types.
Interfering with this could not only disturb response to
pathogens, but could also interrupt tumor immunosurveillance.
To prevent these important side effects, speciﬁc pathways acting
downstream of ZEBs, speciﬁc interaction with leukemia speciﬁc
cofactors or their competition for DNA binding with other
hematopoietic transcription factors, could be targeted. In
that respect, it is interesting to mention that pleiotropic
functions of ZEB proteins seem to utilize different protein
domains,116 and as such the oncogenic roles may be uncoupled
from the tumor suppressor roles. More research will be
required to dissect the mode of action of ZEB1/2 both in
leukemic cells and nontransformed immune cells, which may
open the avenue to less toxic and more speciﬁc therapies for
hematologic malignancies.
Figure 6. Hypothetic model in which ZEB2 and LMO2 use a similar oncogenic mechanism of action in T-cell acute lymphoblastic leukemia. LMO
proteins do not bind DNA themselves, but nucleate a core multiprotein complex by acting as a bridge between 2 bHLH protein dimers that each recognizes a single
E-box. As ZEB2 binds a similar double E-box DNA motif in its target promoters, we speculate that both LMO2 and ZEB2 activate a similar downstream signaling
cascade and may explain the observed phenotypic similarities in Zeb2 overexpressing mouse and CD2-LMO2 transgenic animals. bHLH = basic helix-loop-helix,
CID = CtBP interaction domain, CZF = carboxyterminal zinc ﬁnger domain, E = E-protein, HD = homeobox, NZF = aminoterminal zinc ﬁnger domain.
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